BRIEF-Vaxcyte Advances Adult And Infant Programs For Vax-31, A Potential Best-In-Class, Next-Generation Pneumococcal Conjugate Vaccine

Vaxcyte

Vaxcyte

PCVX

0.00

Jan 22 (Reuters) - Vaxcyte Inc PCVX.O:

  • VAXCYTE ADVANCES ADULT AND INFANT PROGRAMS FOR VAX-31, A POTENTIAL BEST-IN-CLASS, NEXT-GENERATION PNEUMOCOCCAL CONJUGATE VACCINE

  • VAXCYTE: VAX-31 ADULT PHASE 3 NONINFERIORITY TRIAL (OPUS-1) CONTINUES TO ENROLL SUBJECTS, WITH TOPLINE DATA EXPECTED IN FOURTH QUARTER OF 2026

  • VAXCYTE: EXPECTS TO REPORT TOPLINE SAFETY, TOLERABILITY AND IMMUNOGENICITY DATA FROM BOTH OPUS-2 AND OPUS-3 PHASE 3 STUDIES IN FIRST HALF OF 2027

Source text: ID:nGNX5vDqlf

Further company coverage: PCVX.O


((Reuters.Briefs@thomsonreuters.com;))

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.